More trials, more wires, still only incremental cures
LISTEN
Direct audio file (MP3)Today’s signal is straightforward: the cure pipeline keeps expanding—global active cure-related trials now total 21,190—while the last 24 hours added 24 new Wire signals and 3 new Cure research items. The most important caution comes from STAT+, which reports that even high-profile AI-healthcare claims can fail in real emergency-room conditions, creating an evidence gap between promises and bedside performance. On the upside, Nature Medicine highlights two pragmatic ways to close evidence gaps: using real-world evidence to complement lagging women’s health trial data, and reporting a first-in-human randomized trial of inhaled, lung-epithelium-targeted siRNA against RAGE for pulmonary inflammation that was described as safe and well-tolerated. Taken together, the direction is toward measurable translation—less hype, more validation—while the world still needs speed, rigor, and better trials-to-reality bridges. The window is still open.
Global active cure-related trials total 21,190, with 24 new Wire signals and 3 new Cure research items added in the last 24 hours.
Faster, more reliable evidence—rather than bold claims—determines whether cure progress can scale across diseases and patient groups, including women’s health and pulmonary inflammation.
Watch whether real-world evidence approaches and first-in-human randomized translational signals keep producing verifiable outcomes quickly, under the ongoing pressure to close the evidence gap.